Articles tagged with Melanoma Cells
Recent research from the University of Eastern Finland reveals that pro-inflammatory M1 macrophages accelerate melanoma progression through extracellular vesicle secretion. These vesicles contain inflammatory mediators that activate cancer cells, creating a favourable environment for tumour growth and invasiveness.
A study of US veterans has identified a possible link between exposure to Agent Orange and acral melanoma, a rare form of skin cancer. The researchers found that veterans exposed to the herbicide had a 30% higher odds of developing this type of melanoma.
Researchers have established that Candida albicans fungus makes melanoma more aggressive by activating signaling pathways and creating conditions for malignant cells to acquire oxygen and energy. The study's findings suggest potential new avenues for cancer treatment using antifungal therapies.
Researchers have discovered a new way to understand cancer and its vulnerabilities by targeting FSP1, a protein that helps cancer cells survive. The study found that FSP1 inhibitors can effectively reduce the growth of metastatic melanoma cells in lymph nodes.
Researchers at NYU Langone Health discovered that a specific biological pathway explains why many patients with deadly melanoma do not respond to latest cancer treatments. The study found therapeutic targets that could limit melanoma growth in patients with NF1 mutations, suggesting a novel approach for treatment.
A new study using 9 molecular biological technologies analyzed 43,000 data points from 116 patients with melanoma. The analysis revealed a promising approach for developing personalized treatment plans, with 75% of treating specialists finding the recommendations helpful.
Researchers at Sutter Health have discovered early signs of clinical benefit from niraparib, a PARP inhibitor, in patients with advanced melanoma whose tumors had specific genetic changes impacting DNA repair. The study found a disease control rate of 64% and potential as a biomarker for treatment response.
Researchers discovered that endoperoxides derived from ergosterol and 7-dehydrocholesterol induce the death of melanoma cells. This finding paves the way for expanding the use of photodynamic therapy in fighting skin cancer.
Researchers found that GSK3β becomes increasingly active in melanoma cells during treatment, helping them survive and adapt despite BRAF inhibitors. Treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth, suggesting blocking this protein could restore sensitivity to treatment.
Researchers at Institute for Systems Biology (ISB) have discovered a non-genetic adaptation mechanism that allows melanoma cells to evade BRAF inhibitors within hours. By blocking this early response with a combination therapy approach, the study aims to improve treatment outcomes and prolong the effectiveness of existing treatments.
Researchers identified S6K2 as a potential target for treating NRAS MUT melanoma, which accounts for 30% of all melanoma cases. The team found that silencing S6K2 killed cancer cells by disrupting lipid metabolism, and combining treatment with two compounds improved therapeutic outcomes.
Researchers at Weill Cornell Medicine identified a unique enzyme called FTSJ1 that enables melanoma cells to escape oxidative stress and spread. By targeting this enzyme, therapies may prevent or treat metastasis with minimal side effects.
Researchers have defined a molecular mechanism controlling PD-1 expression in melanoma cells, revealing a critical type I interferon-JAK/STAT signaling circuit. Inhibition of this pathway reduces PD-1 levels on melanoma cells and efficacy of immune checkpoint therapy.
Researchers discovered a new way to effectively treat melanoma using nutrients to reactivate suppressed metabolic pathways in cancer cells. The innovative treatment, involving tyrosine nanomicelles, showed promising results in mice and lab-derived human cells, inhibiting tumour growth and reducing glycolysis.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
Researchers develop molecular jackhammers that use aminocyanine molecules to create plasmons, which rupture melanoma cell membranes with high efficiency. The method showed a 99% success rate against lab cultures of human melanoma cells and cured half of the mice with melanoma tumors.
Researchers discovered a new role for extracellular signal-regulated kinase (ERK) in a pathway activated by interferon-gamma that leads to cancer cell death. Hyperactivation of ERK causes stress in cells, triggering cell death through specific proteins DR5 and NOXA.
A phase I trial found that combining fecal transplants with immunotherapy is safe and shows promise in improving clinical responses in 65% of patients. The study used healthy donor microbiome to enhance immune system attack on cancer, offering a new paradigm shift in melanoma treatment.
Researchers discovered that melanoma skin cancer cells adopt an efficient style of movement called rounded-amoeboid migration, which requires less energy than traditional cell movement. This process involves reshaping mitochondria to operate in a low-power mode, allowing cells to survive in stressful environments.
A new study has identified a protein called LAP1 that makes melanoma cells more aggressive by changing their nucleus shape. The protein allows cancer cells to migrate and spread throughout the body, leading to poor outcomes in patients.
Researchers at UNIGE and LMU discovered that immune system's anti-tumour activity peaks in the morning. Tumours implanted at night grew faster than those implanted in the afternoon. Administering immunotherapy treatments early morning significantly enhanced their effectiveness, suggesting a new strategy for cancer treatment.
Researchers at the University of Pittsburgh School of Medicine have discovered a genetic link between melanoma tumors and telomere maintenance, which could lead to new treatments for the disease. The study found that mutations in the TPP1 gene stimulate telomerase activity, promoting long telomeres that enable cancer cells to divide in...
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
A recent study has found that vitamin D deficiency is associated with lower overall survival rates in melanoma patients. The research, presented at the European Academy of Dermatology and Venereology Congress, suggests that vitamin D levels play a significant role in determining patient outcomes.
A phase II study found that treating late-stage, treatment-resistant melanoma patients with a combination of Azacitidine and Carboplatin significantly increases their survival times. The treatment re-sensitized cancer cells to immunotherapy, allowing the body's immune system to fight the cancer.
Researchers at Sanford Burnham Prebys have shown that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. The study identifies GCDH as the crucial enzyme in metabolizing lysine and tryptophan, amino acids essential for human health.
Researchers at the University of São Paulo found that deactivating the light-sensitive protein melanopsin slows melanoma progression in animal experiments. The study, published in Communications Biology, suggests that melanopsin acts as an oncogene in melanoma, a type of skin cancer.
Researchers at the University of Pittsburgh have discovered that even terminally exhausted T cells retain some capacity to function again. They identified approaches to overcome exhaustion by targeting co-stimulation pathways and reprogramming T cells to be resistant to hypoxia, a common tumor microenvironmental signal.
Researchers at the Centre for Genomic Regulation have identified PDIA6 as a key protein involved in driving melanoma malignancy. The study found that PDIA6 promotes melanoma cell growth by binding to RNA molecules inside tumor cells, making it a promising therapeutic target.
Researchers from the University of Gothenburg found that assessing melanoma thickness is challenging for both human dermatologists and machine-learning algorithms. Despite differences in success rates, both groups achieved comparable results when evaluating dermoscopic images, highlighting the need for further study to improve diagnost...
A new study from Penn State College of Medicine finds that a unique combination of drugs can activate natural killer cell immunity in mice, which may also reinvigorate T cells to attack melanoma tumors. The combination targets proteins AKT and WEE1, increasing p53 pathway activity and enhancing natural killer cell infiltration.
New research reveals that age-induced changes in lung fibroblasts reactivate dormant melanoma cells, promoting growth and metastasis. The study found that WNT5A signaling pathway regulates tumor cell dormancy and metastasis initiation, with increased sFRP1 secretion facilitating reactivation in the aged lung.
Researchers at Washington State University have discovered that a specific population of CD4-positive helper T cells initiates antitumor immunity defenses, which can enhance the effectiveness of killer cell attacks on cancer cells. This finding holds promise for improving cancer immunotherapy response rates.
A Brazilian group developed a peptide called Rb4 that triggers necrosis in murine melanoma cells and inhibits the viability of human cancer cells. In mice, Rb4 reduced lung metastasis and slowed subcutaneous melanoma growth, increasing survival by 25%.
Researchers have identified a new strain of the myxoma virus that has enabled it to leap from European rabbits to Iberian hares, causing lethal disease in both species. The study suggests that this viral adaptation may also improve the virus's ability to replicate in human cancer cells.
Researchers developed a blood test to detect circulating melanoma cells, which can help diagnose skin cancer and monitor treatment response. The test uses the Melanoma-specific OncoBean platform conjugated with melanoma-specific antibodies.
Researchers at UC Irvine and IIT develop ALY101, a compound that blocks protein-protein interactions crucial for cancer and rare disease progression. The findings validate a new approach to structure-based drug design, with potential applications in monotherapy or combination regimens.
Researchers have identified a gene mutation in ARID2 that signals the development of aggressively metastatic melanoma. The study suggests patients with this mutation may require different treatment approaches to manage their cancer effectively. Further research is underway to refine this understanding and improve patient outcomes.
The FDA has approved a novel combination therapy of relatlimab and nivolumab for patients with metastatic or inoperable melanoma. The treatment significantly delayed cancer progression time compared to nivolumab alone. LAG-3 blockade reinvigorated T cell anti-tumor activity, establishing the pathway as the third immune checkpoint target.
Dr. Steven A. Rosenberg's pioneering work on IL-2 and its use in treating metastatic melanoma and other cancers led to the FDA approval of first U.S.-born cancer immunotherapy. His subsequent research on CAR T-cell therapy has resulted in promising clinical results for various types of cancer.
Researchers from H. Lee Moffitt Cancer Center identified unique features of acral melanoma, including immune checkpoints that could represent novel therapeutic targets for this neglected disease. The study's findings may lead to more effective treatments for patients with acral melanoma.
Melanoma skin cancer cells use Alzheimer's protein amyloid beta to survive in the brain, evading immune detection. A new study reveals a potential treatment target to counter this mechanism.
A new study suggests that microorganisms hindering treatment have a greater influence than those enhancing it, with around 1 year after treatment begins the gut microbiota becomes a dominant factor. The research sheds light on the interaction between the gut microbiome and cancer immunotherapy response.
Patients with Merkel cell carcinoma face a high risk of recurrence, with 95% of cases occurring within the first three years. The study found that advanced age, male sex, immunosuppression, and known primary lesions are associated with higher recurrence rates, highlighting the need for targeted surveillance efforts.
Melanoma cells release small packages containing the protein NGFR, which primes nearby lymph nodes to form new vessels and encourage cancer spread. This process, called lymphangiogenesis, may help doctors determine which patients need more aggressive treatment.
A potential vaccine stimulating skin antioxidant production may help prevent skin cancer. Researchers at Oregon State University have identified TR1, a protein critical to the skin's antioxidant network, as a key target for this approach.
A new study found that high dietary fiber intake and no probiotic use are associated with better disease non-progression among melanoma patients on ICB therapy. The results support the idea that a high-fiber diet may be crucial for anti-tumor immunity.
Scientists have identified the transcription factor Blimp1 as a new critical regulator of tumor-infiltrating regulatory T cells. Disrupting Blimp1 in these cells remodels the tumor microenvironment and augments the response to immunotherapy, promoting improved tumor control and anti-tumor immunity.
Researchers found that environmental signals affect melanocytes, causing them to divide uncontrollably and turn into melanoma. The study provides a foundation for researching potential biomarkers and topical agents to prevent or treat melanoma.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Researchers at Penn Medicine and The Wistar Institute will explore new treatments for skin cancer using the grant, including projects on exosomal PD-L1 and autophagy inhibition. The team aims to improve patient outcomes and develop more effective immunotherapy strategies.
A novel population of long-lived T cells, called 'lymph node resident memory T cells,' provides protection against melanoma by persisting in lymph nodes. These cells were found to counteract melanoma spreading in mice and predicted better outcomes for human melanoma patients with lymph node metastases.
A new combination treatment has shown significant tumor shrinkage and prolonged survival in patients with metastatic uveal melanoma. The treatment, which targets HDAC and PD-1 proteins, was found to work better in tumors with active BAP1 genes, a key discovery that may lead to improved survival rates.
Researchers found that UVB radiation from the sun causes chemical changes to DNA, leading to disease-causing mutations. This discovery sheds light on the origins of melanoma and highlights the importance of prevention efforts.
Researchers at WashU Medicine have shown that cell-based immunotherapy using natural killer cells may be effective against solid tumors, including melanoma. The therapy has been successful in treating patients with recurrent leukemia and other blood cancers.
A study by Massachusetts General Hospital researchers discovered that a subset of white blood cells, known as CD4+ T cells, reside in moles and can be activated to attack melanoma. This approach could potentially broaden the body's antitumor response and overcome current cancer immunotherapies.
A recent study published in the Oncogene Journal revealed that targeting HIF-1α significantly inhibited melanoma growth and amplified immune cell infiltration into tumour microenvironment. The discovery provides a valuable new target for making resistant melanomas more vulnerable to available anti-cancer treatments.
A Salk study reveals the connection between CRTC3 and melanin production, finding that eliminating the protein can reduce melanoma cell aggression. The researchers also discovered two cellular communications systems converge on CRTC3, suggesting it as a potential target for developing new treatments.
Researchers at Huntsman Cancer Institute discovered that nicotinamide phosphoribosyltransferase (NAMPT) plays a key role in how immune cells fight melanoma tumors. The study found that disrupting the NAMPT pathway impairs antitumor function, and novel therapies targeting this pathway may lead to improved outcomes for patients.